SynthesisDermatology and therapy2026
New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review.
Synthesis in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biologic agents, including the interleukin-23 (IL-23) inhibitors (IL-23is) guselkumab, risankizumab, and tildrakizumab, are effective therapies for the treatment of psoriasis (PsO) and psoriatic arthritis (PsA). However, the risk of latent TB infection (LTBI) reactivation or new tuberculosis (TB) infection is of question, given documented evidence of occurrence of cases in patients with PsO and PsA treated with biologics with other mechanisms of action, and the relatively high prevalence of TB in some Asian Pacific (APAC) countries. We conducted a systematic literature review to summarize published evidence related to reactivation of LTBI or new TB infections among IL-23i-treated patients with PsO or PsA, with a focus on the APAC region. We searched the EMBASE, MEDLINE, MEDLINE In-Process, CNKI, Wanfang, ICHUSHI, KOREAMED, and AIRITI databases and gray literature sources for reports on randomized controlled trials and real-world observational studies reporting reactivation of LTBI or new TB infections among IL-23i-treated patients with PsO or PsA. A total of 58 publications from 41 studies met prespecified inclusion criteria, including 9 publications from 8 studies in APAC countries. No LTBI reactivation events or new TB cases were observed in 33 of 34 studies that enrolled IL-23i-treated patients with PsO, including patients with LTBI who did not complete chemoprophylaxis. In one observational study, LTBI reactivation was reported in a single risankizumab-treated patient. Similarly, no cases of LTBI reactivation or new TB cases were observed in 8 studies enrolling IL-23i-treated patients with PsA. The results summarized here suggest that the risks of new TB infections or LTBI reactivation are minimal among IL-23i-treated patients with PsO or PsA. Routine testing for LTBI in patients initiating IL-23i treatment should not be required, particularly in regions with low TB prevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.